Hemagen Diagnostics, Inc.
HMGN
Rank in Stocks
#34759
Hemagen Diagnostics, Inc., a global biotechnology firm, specializes in... Hemagen Diagnostics, Inc., a global biotechnology firm, specializes in delivering clinical diagnostic solutions for both human and animal health. The company designs, manufactures, and distributes the VIRGO product line, a series of human clinical immunoassays used for identifying autoimmune and infectious diseases, as well as acute phase proteins. Its comprehensive human diagnostic portfolio also encompasses Universal IFA components, various supplies, controls, calibrators, accessories, H-rotors, reagents, electrodes, equipment, and specialized assays covering conditions such as Chagas, acute phase proteins, and cytokines. For the veterinary market, Hemagen Diagnostics provides diagnostic equipment, reagents, consumables, accessories, and electrodes crucial for chemistry, hematology, and electrolyte analysis. The company reaches a diverse customer base, including laboratories, hospitals, and blood banks, through both direct sales and an extensive distribution network. Established in 1985, Hemagen Diagnostics maintains its headquarters in Columbia, Maryland.
Share Price
$0.0002
Last synced: 2026-11-10
Market Cap
$3.10K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Hemagen Diagnostics, Inc. (HMGN)
Category
Healthcare
EPS for Hemagen Diagnostics, Inc. (HMGN)
EPS as of September 2012 TTM: $-0.06
According to Hemagen Diagnostics, Inc.'s latest financial reports, its current EPS (TTM) is $-0.06. At the end of 2012 the company had an EPS of $-0.06, equal to its 2011 EPS of $-0.06.
EPS history for Hemagen Diagnostics, Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.06 | 0.83% |
| 2012 | $-0.06 | -2.50% |
| 2011 | $-0.06 | 500.00% |
| 2010 | $-0.01 | -80.00% |
| 2009 | $-0.05 | -266.67% |
| 2008 | $0.03 | -150.00% |
| 2007 | $-0.06 | -400.00% |
| 2006 | $0.02 | -122.22% |
| 2005 | $-0.09 | -75.00% |
| 2004 | $-0.36 | 176.92% |
| 2003 | $-0.13 | -27.78% |
| 2002 | $-0.18 | -21.74% |
| 2001 | $-0.23 | -56.60% |
| 2000 | $-0.53 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -25,984.30% |
US
|
|
| $-7.07 | 11,585.95% |
US
|
|
| $-5.29 | 8,643.80% |
AU
|
|
| $12.88 | -21,389.42% |
BE
|
|
| $21.56 | -35,736.36% |
NL
|
Questions about Hemagen Diagnostics, Inc.'s earnings per share (EPS)
What is Hemagen Diagnostics, Inc.'s earnings per share (EPS)?
Hemagen Diagnostics, Inc.'s earnings per share (EPS) over the last twelve months is $-0.06, as of Sep 2012.
What was Hemagen Diagnostics, Inc.'s earnings per share (EPS) in 2012?
In 2012, Hemagen Diagnostics, Inc.'s earnings per share (EPS) was $-0.06, compared with $-0.06 in 2011.
How has Hemagen Diagnostics, Inc.'s earnings per share (EPS) changed since 2007?
From 2007 to 2012, Hemagen Diagnostics, Inc.'s earnings per share (EPS) was highest in 2008 ($0.03) and lowest in 2012 ($-0.06).
How does Hemagen Diagnostics, Inc.'s earnings per share (EPS) compare with similar companies?
Hemagen Diagnostics, Inc.'s earnings per share (EPS) ($-0.06) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.